Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
Tanaka K, Toyota S, Akiyama M, Wakimoto N, Nakamura Y, Najima Y, Doki N, Kakihana K, Igarashi A, Kobayashi T, Ohashi K, Kudo D, Shinagawa A, Takano H, Fujio T, Okoshi Y, Hori M, Kumagai T, Saito T, Mukae J, Yamamoto K, Tsutsumi I, Komeno T, Yoshida C, Yamamoto M, Kojima H; on behalf of the Ochanomizu Hematology Study Group. Tanaka K, et al. Among authors: komeno t. Acta Haematol. 2019;141(2):111-118. doi: 10.1159/000495338. Epub 2019 Feb 6. Acta Haematol. 2019. PMID: 30726834 Clinical Trial.
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Cho Y, Hori M, Okoshi Y, Fujisawa F, Shinagawa A, Kudo D, Komeno T, Yoshida C, Katsura Y, Ota I, Shimizu S, Kamoshita M, Sasaki K, Tanaka K, Mukai HY, Kojima H. Cho Y, et al. Among authors: komeno t. Acta Haematol. 2015;134(1):25-31. doi: 10.1159/000369445. Epub 2015 Apr 3. Acta Haematol. 2015. PMID: 25871926 Clinical Trial.
A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation.
Yamamoto M, Ohashi K, Kakihana K, Nakamura Y, Komeno T, Kojima H, Morita S, Sakamaki H. Yamamoto M, et al. Among authors: komeno t. Mol Clin Oncol. 2016 Jun;4(6):965-970. doi: 10.3892/mco.2016.833. Epub 2016 Mar 28. Mol Clin Oncol. 2016. PMID: 27313858 Free PMC article.
Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification.
Kojima H, Hasegawa Y, Suzukawa K, Mukai HY, Kaneko S, Kobayashi T, Kamoshita M, Shinagawa A, Komeno T, Komatsu T, Mitsuhashi S, Kawachi Y, Yamashita Y, Mori N, Nagasawa T. Kojima H, et al. Among authors: komeno t. Leuk Res. 2004 Dec;28(12):1287-92. doi: 10.1016/j.leukres.2004.04.016. Leuk Res. 2004. PMID: 15475070
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.
Yoshida C, Komeno T, Hori M, Kimura T, Fujii M, Okoshi Y, Suzukawa K, Chiba S, Hasegawa Y, Mukai HY, Ito T, Shimizu S, Kamoshita M, Kudo D, Shinagawa A, Chikatsu N, Monma Y, Watanabe N, Kojima H. Yoshida C, et al. Among authors: komeno t. Int J Hematol. 2011 May;93(5):618-623. doi: 10.1007/s12185-011-0838-3. Epub 2011 Apr 22. Int J Hematol. 2011. PMID: 21523339
98 results